TRV-120027 TFA (C007B-431526)

TRV120027 TFA, a β-arrestin-1 -biased agonist of the angiotensin II receptor type 1 (AT1R) , engages ß-arrestins while blocking G-protein signaling. TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) couplAppearance:SolidIC50& Target:IC50: the angiotensin II receptor type 1 (AT1R)In Vitro:TRV120027 TFA (100 nM) significantly increases the AT1R and TRPC3 association with the immunoprecipitated β-arrestin-1 in HEK293 cells co-transfected with Flag-AT1R-cherry, HA-β-arrestin-1 and TRPC3-GFP. TRV120027 TFA (100 nM) induces an [Ca 2+ ]i inIn Vivo:TRV120027 TFA (intravenous injection; 0.3 or 1.5 µg/kg per minute; infusion rate, 0.5 mL/min) when added to furosemide decreases cardiac preload and afterload, systemic and renal vascular resistances, and left ventricular external work while increasing caBiological Activity:TRV120027 TFA, a β-arrestin-1 -biased agonist of the angiotensin II receptor type 1 (AT1R) , engages ß-arrestins while blocking G-protein signaling . TRV120027xa0TFA inducesxa0acutexa0catecholaminexa0secretionxa0through cation channel subfamily C3 (TR.

Specifications and Purity: ≥98%

Molecular Formula: C45H68F3N13O12

Molecular Weight: 1040.1